These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 33786232)
21. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Shoskes DA; Nickel JC; Dolinga R; Prots D Urology; 2009 Mar; 73(3):538-42; discussion 542-3. PubMed ID: 19118880 [TBL] [Abstract][Full Text] [Related]
22. Correlation of Ultrasonically Determined Bladder Wall Thickness and Prostatic Calcification With the Urinary, Psychosocial Dysfunction, Organ Specific, Infection and Neurological/Systemic Symptoms, and Tenderness Scoring System. Arda E; Cakiroglu B; Akdeniz E; Akdere H; Yuksel I; Senturk AB Urology; 2019 Feb; 124():218-222. PubMed ID: 30528713 [TBL] [Abstract][Full Text] [Related]
23. Clinical Phenotyping and Multimodal Treatment of Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome From the Middle East and North Africa: Determining Treatment Outcomes and Predictors of Clinical Improvement. Majzoub A; Mahdi M; Khalil I; Saeedi AA; Rumaihi KA Urology; 2022 Sep; 167():179-184. PubMed ID: 35533765 [TBL] [Abstract][Full Text] [Related]
25. National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis/chronic pelvic pain syndrome. Wagenlehner FM; van Till JW; Magri V; Perletti G; Houbiers JG; Weidner W; Nickel JC Eur Urol; 2013 May; 63(5):953-9. PubMed ID: 23141933 [TBL] [Abstract][Full Text] [Related]
26. Utility of trigger point injection as an adjunct to physical therapy in men with chronic prostatitis/chronic pelvic pain syndrome. Tadros NN; Shah AB; Shoskes DA Transl Androl Urol; 2017 Jun; 6(3):534-537. PubMed ID: 28725596 [TBL] [Abstract][Full Text] [Related]
28. Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study. Matsukawa Y; Naito Y; Funahashi Y; Ishida S; Fujita T; Tochigi K; Kato M; Gotoh M Neurourol Urodyn; 2020 Sep; 39(7):1994-2002. PubMed ID: 32648985 [TBL] [Abstract][Full Text] [Related]
29. Inclusion of erectile domain to UPOINT phenotype does not improve correlation with symptom severity in men with chronic prostatitis/chronic pelvic pain syndrome. Samplaski MK; Li J; Shoskes DA Urology; 2011 Sep; 78(3):653-8. PubMed ID: 21664651 [TBL] [Abstract][Full Text] [Related]
30. Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome: An Italian prospective multicenter study. Presicce F; Barrese F; Cantiani A; Filianoti A; Tuzzolo D; Di Palma P; Lauretti S; Brunori S; Martini M Asian J Urol; 2022 Apr; 9(2):139-145. PubMed ID: 35509480 [TBL] [Abstract][Full Text] [Related]
31. Relationship between premature ejaculation and chronic prostatitis/chronic pelvic pain syndrome. Lee JH; Lee SW J Sex Med; 2015 Mar; 12(3):697-704. PubMed ID: 25475760 [TBL] [Abstract][Full Text] [Related]
33. [UPOINT system: a new diagnostic/therapeutic algorithm for chronic prostatitis/chronic pelvic pain syndrome]. Zhang ZC; Peng J Zhonghua Nan Ke Xue; 2013 Jul; 19(7):579-82. PubMed ID: 23926671 [TBL] [Abstract][Full Text] [Related]
34. Fluoxetine ameliorates symptoms of refractory chronic prostatitis/chronic pelvic pain syndrome. Xia D; Wang P; Chen J; Wang S; Jiang H Chin Med J (Engl); 2011 Jul; 124(14):2158-61. PubMed ID: 21933619 [TBL] [Abstract][Full Text] [Related]
35. Impact of chronic prostatitis-like symptoms on the quality of life in a large group of men. Walz J; Perrotte P; Hutterer G; Suardi N; Jeldres C; Bénard F; Valiquette L; Karakiewicz PI BJU Int; 2007 Dec; 100(6):1307-11. PubMed ID: 17941922 [TBL] [Abstract][Full Text] [Related]
36. Predictors of quality of life and pain in chronic prostatitis/chronic pelvic pain syndrome: findings from the National Institutes of Health Chronic Prostatitis Cohort Study. Tripp DA; Curtis Nickel J; Landis JR; Wang YL; Knauss JS; BJU Int; 2004 Dec; 94(9):1279-82. PubMed ID: 15610105 [TBL] [Abstract][Full Text] [Related]
37. [Use of cytomedins in case of prostatic involvement in chronic prostatitis according to UPOINT classification]. Ergakov DV; Martov AG; Turin DE Urologiia; 2019 Jul; (3):31-35. PubMed ID: 31356010 [TBL] [Abstract][Full Text] [Related]
38. Using the UPOINT system to manage men with chronic pelvic pain syndrome. Bryk DJ; Shoskes DA Arab J Urol; 2021; 19(3):387-393. PubMed ID: 34552790 [TBL] [Abstract][Full Text] [Related]
39. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Mehik A; Alas P; Nickel JC; Sarpola A; Helström PJ Urology; 2003 Sep; 62(3):425-9. PubMed ID: 12946740 [TBL] [Abstract][Full Text] [Related]
40. Failure of a monotherapy strategy for difficult chronic prostatitis/chronic pelvic pain syndrome. Nickel JC; Downey J; Ardern D; Clark J; Nickel K J Urol; 2004 Aug; 172(2):551-4. PubMed ID: 15247727 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]